File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Nephroureterectomy for upper tract urothelial carcinomas: clinical outcomes and predictors, 15 years experience at a tertiary centre in Hong Kong

TitleNephroureterectomy for upper tract urothelial carcinomas: clinical outcomes and predictors, 15 years experience at a tertiary centre in Hong Kong
Authors
Issue Date2019
PublisherWiley-Blackwell Publishing Ltd. The Journal's web site is located at http://www.bjui.org/
Citation
The 23rd Hong Kong Urological Assoication Annual Scientific Meeting, Hong Kong, 4 November 2018. In BJU International, v. 123 n. S1, p. 15 How to Cite?
AbstractObjective: Nephroureterectomy (NU) remains the gold standard for treating localised upper tract urothelial carcinomas. We reviewed nephroureterectomies performed at Queen Mary Hospital over a 10‐year period to reveal overall survival (OS) and disease‐free survival (DFS) outcomes, along with potential clinical and pathological factors that might predict prognosis. Patients and Methods: Patients with localised urothelial carcinoma of the renal pelvis or ureter treated with NU at Queen Mary Hospital between 2009–2018 were retrospectively identified via the Hospital Authority CEDARS system. Results: A total of 58 nephroureterectomies were performed. There were 33 males and 25 females. Mean age at operation was 72.41 years. 34.38% were smokers. 25 patients have died at the time of analysis. Mean follow‐up time was 2.60 years. The median OS is 3.54 years (95% CI 2.43‐NA). 3‐year OS is 57.5% (95% CI 0.447–0.741). Median DFS is 1.852 years (95% CI 0.653‐NA). Age‐adjusted Charlson Comorbidity Index (CCI) (HR=1.42, 95% CI 1.16–1.73, p = 0.001) and positive pathological margins (HR=9.91, 95% CI 3.17–31.0, p < 0.0001) were shown to be predictive of overall survival in multivariate Cox regression model. Conclusion: Nephroureterectomy may offer prolonged survival in carefully selected patients with urothelial carcinoma.
DescriptionPoster Presentation
Persistent Identifierhttp://hdl.handle.net/10722/266481
ISSN
2017 Impact Factor: 4.688
2015 SCImago Journal Rankings: 2.009

 

DC FieldValueLanguage
dc.contributor.authorTang, C-
dc.contributor.authorLai, TCT-
dc.contributor.authorYuen, SKK-
dc.contributor.authorTsang, CF-
dc.contributor.authorLam, PW-
dc.contributor.authorHo, SHB-
dc.contributor.authorNg, ATL-
dc.contributor.authorMa, WK-
dc.contributor.authorTsu, HLJ-
dc.date.accessioned2019-01-18T08:20:31Z-
dc.date.available2019-01-18T08:20:31Z-
dc.date.issued2019-
dc.identifier.citationThe 23rd Hong Kong Urological Assoication Annual Scientific Meeting, Hong Kong, 4 November 2018. In BJU International, v. 123 n. S1, p. 15-
dc.identifier.issn1464-4096-
dc.identifier.urihttp://hdl.handle.net/10722/266481-
dc.descriptionPoster Presentation-
dc.description.abstractObjective: Nephroureterectomy (NU) remains the gold standard for treating localised upper tract urothelial carcinomas. We reviewed nephroureterectomies performed at Queen Mary Hospital over a 10‐year period to reveal overall survival (OS) and disease‐free survival (DFS) outcomes, along with potential clinical and pathological factors that might predict prognosis. Patients and Methods: Patients with localised urothelial carcinoma of the renal pelvis or ureter treated with NU at Queen Mary Hospital between 2009–2018 were retrospectively identified via the Hospital Authority CEDARS system. Results: A total of 58 nephroureterectomies were performed. There were 33 males and 25 females. Mean age at operation was 72.41 years. 34.38% were smokers. 25 patients have died at the time of analysis. Mean follow‐up time was 2.60 years. The median OS is 3.54 years (95% CI 2.43‐NA). 3‐year OS is 57.5% (95% CI 0.447–0.741). Median DFS is 1.852 years (95% CI 0.653‐NA). Age‐adjusted Charlson Comorbidity Index (CCI) (HR=1.42, 95% CI 1.16–1.73, p = 0.001) and positive pathological margins (HR=9.91, 95% CI 3.17–31.0, p < 0.0001) were shown to be predictive of overall survival in multivariate Cox regression model. Conclusion: Nephroureterectomy may offer prolonged survival in carefully selected patients with urothelial carcinoma.-
dc.languageeng-
dc.publisherWiley-Blackwell Publishing Ltd. The Journal's web site is located at http://www.bjui.org/-
dc.relation.ispartofBJU International-
dc.rightsPreprint This is the pre-peer reviewed version of the following article: [FULL CITE], which has been published in final form at [Link to final article using the DOI]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions. Postprint This is the peer reviewed version of the following article: [FULL CITE], which has been published in final form at [Link to final article using the DOI]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.-
dc.titleNephroureterectomy for upper tract urothelial carcinomas: clinical outcomes and predictors, 15 years experience at a tertiary centre in Hong Kong-
dc.typeConference_Paper-
dc.identifier.emailLam, PW: lamwayne@hku.hk-
dc.identifier.emailHo, SHB: hobrian@hku.hk-
dc.identifier.emailNg, ATL: ada5022@hku.hk-
dc.identifier.emailMa, WK: mwk054@hku.hk-
dc.identifier.emailTsu, HLJ: jamestsu@hku.hk-
dc.identifier.authorityLam, PW=rp02305-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1111/bju.14677-
dc.identifier.hkuros296738-
dc.identifier.volume123-
dc.identifier.issueS1-
dc.identifier.spage15-
dc.identifier.epage15-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats